Early treatment of Favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control studyArticle Published on 2022-12-012022-11-15 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 치료기술, 치료제, [키워드] 95% CI adjusted hazard ratio Antiviral ARMS clinical clinical condition Clinical improvement complications control arm COVID-19 COVID-19 patient Day defined early treatment Effect Efficacy enrolled enrolment faster Favipiravir female FPV investigated likelihood median median time mild case mild pneumonia multicentre Patient PCR-confirmed Pneumonia primary endpoint randomized control study RdRP RdRp inhibitor registry risk of COVID-19 SARS-CoV-2-infected patient score significantly higher supportive care sustained symptomatic Thailand Treatment viral clearance Viral detection [DOI] 10.1080/22221751.2022.2117092 PMC 바로가기
Combination therapy with remdesivir and immunomodulators improves respiratory status in COVID-19: A retrospective studyArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 치료제, [키워드] 95% confidence interval Analysis Baricitinib baseline benefit body mass index combination therapy Concomitant contributed control group coronavirus disease COVID-19 COVID-19 patient COVID-19 patients Day Diabetes Mellitus examined faster greater hazard ratio immunomodulator immunomodulators IMPROVE in both group independent investigated median outcome Oxygen administration Patient patients Prognostic factors Remdesivir respiratory recovery retrospective Retrospective study severity single-center study standard treatment supplemental oxygen survival synergistic therapy Tocilizumab treated two group [DOI] 10.1002/jmv.28037 PMC 바로가기
SARS-CoV-2 RNA load in nasopharyngeal specimens from outpatients with breakthrough COVID-19 due to Omicron BA.1 and BA.2Article Published on 2022-12-012022-11-16 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, [키워드] acute respiratory syndrome All participant BA.1 BA.2 Booster vaccine caused collected comparable composed coronavirus coronavirus disease COVID-19 Day Diagnosis dose elapsed had no Infection log median median age nasopharyngeal specimen omicron Omicron variant Outpatient Patient reached retrospective RNA SARS-CoV-2 SARS-CoV-2 RNA Support symptom onset TaqPath Thermo Fisher Scientific time Transmissibility upper respiratory tract URT vaccination schedule Vaccine vaccine dose Viral load viral RNA load was used [DOI] 10.1002/jmv.28079 PMC 바로가기
Immunogenicity and safety of SpikoGen®, an adjuvanted recombinant SARS-CoV-2 spike protein vaccine as a homologous and heterologous booster vaccination: A randomized placebo-controlled trialArticle Published on 2022-11-012022-11-15 Journal: Immunology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] 95% confidence interval Administered adverse event approved assessment booster booster dose booster vaccination clinical trials Course COVID-19 COVID-19 vaccination COVID-19 vaccine cross-neutralization cross-neutralization. Day double-blind Effect fatigue Heterologous homologous humoral immunogenic immunogenicity incidence injection site pain Local Neutralizing antibodies neutralizing antibody outcome participant Participants Placebo placebo-controlled primary immunogenicity Randomized randomized placebo-controlled trial Recombinant spike protein reported robust Safe Safety safety profile saline placebo SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2 variants Serious Adverse Event Serious Adverse Events Seroconversion seroconversion rate shown SpikoGen subunit the placebo group Trial Vaccine was performed [DOI] 10.1111/imm.13540 PMC 바로가기
Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19Article Published on 2022-10-192022-11-15 Journal: PLoS Medicine [Category] COVID19(2023년), SARS, 치료제, [키워드] 95% CI Administered administration Adverse affected analysed antiviral therapy Antiviral treatment ARMS baseline changed Combination combination therapy concentrations conducted coronavirus 2 COVID-19 COVID-19 pandemic Day Dose escalation doses double-blind double-blind trial drug level effective Efficacy evaluate the effect event Favipiravir healthy Interaction Lopinavir-ritonavir measure monotherapy Odds ratio Outpatient participant Participants Phase 2 Placebo placebo-controlled placebo-controlled trial placebos plasma primary analysis Primary outcome provided randomised recruited reduced respiratory SARS-CoV-2 SARS-CoV-2 viral load significant interaction significantly study population symptom onset the mean trajectory Treatment undetectable United Kingdom Viral load virus [DOI] 10.1371/journal.pmed.1004120 PMC 바로가기
Six-month humoral immune response to inactivated COVID-19 vaccine among people living with HIVArticle Published on 2022-10-172022-11-15 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 진단, [키워드] 95% CI conducted Control COVID-19 COVID-19 vaccine Day decrease determine dropped Effect ELISA enrolled examined extension FIVE geometric geometric mean concentration GMC GMCs humoral humoral immune response IgG IgG antibody inactivated Inactivated COVID-19 vaccine investigated longitudinal longitudinal humoral response NAb Neutralizing Neutralizing antibodies no significant difference peaked People living with HIV (PLWH) PLWH positive SARS-CoV-2 neutralizing antibody Seroconversion seroconversion rate Seven significantly significantly lower specific IgM two group two groups vaccination with HIV [DOI] 10.3389/fimmu.2022.988304 PMC 바로가기
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Codetection With Influenza A and Other Respiratory Viruses Among School-Aged Children and Their Household Members-12 March 2020 to 22 February 2022, Dane County, WisconsinArticle Published on 2022-10-032022-11-15 Journal: Clinical Infectious Diseases: An Official Publicat [Category] COVID19(2023년), SARS, 진단, 치료기술, 치료제, [키워드] acute respiratory illness acute respiratory syndrome affected another respiratory virus children circulation codetection concurrent coronavirus coronavirus 2 Day demographic Enrollment evaluate household Households individual Influenza nasal Other other respiratory virus participant pathogen polymerase chain positive recruitment respiratory respiratory pathogen respiratory virus respiratory viruses SARS-CoV-2 specimen Symptom target tested [DOI] 10.1093/cid/ciac487 PMC 바로가기
Impact of SARS-CoV-2 viral load and duration of symptoms before hospital admission on the mortality of hospitalized COVID-19 patientsArticle Published on 2022-10-012022-11-15 Journal: Infection [Category] COVID19(2023년), SARS, 치료제, [키워드] Admission Analysis antivirals clinical manifestation collected COVID-19 COVID19 Ct value cycle threshold Day Days of symptoms demographic duration of symptom Efficacy evaluate Factor Factors highest Hospital admission hospitalized COVID-19 patient hospitalized patient identify Impact Inclusion laboratory parameter Mortality mortality rate Multivariate analysis Nasopharyngeal swab Patient performed positive predictor reverse transcription rRT-PCR SARS-CoV-2 viral load study population symptoms onset three group Viral load was performed [DOI] 10.1007/s15010-022-01833-8 PMC 바로가기
Integrating basic science with translational research: the 13th International Podocyte Conference 2021Short communication Published on 2022-10-012022-10-05 Journal: Kidney international [Category] 비임상, [키워드] 13th International Podocyte Conference Abstract addition Basic science Clinicians Conference coronavirus disease COVID-19 Day Diagnosis global pandemic introduced meeting report offered pandemic pathway Patient patients podocyte podocyte2021 Research researcher researchers Resilience selected Therapies translational [DOI] 10.1016/j.kint.2022.07.021 [Article Type] Short communication
Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients: the SENCOVAC studyArticle Published on 2022-09-222022-11-15 Journal: Nephrology, dialysis, transplantation : official p [Category] SARS, 진단, [키워드] absence acute respiratory syndrome Adjusted analysis Adverse analysed antibodies antibody Antibody Response baseline BNT162b2 vaccine booster dose chronic Chronic kidney disease CKD cohorts cohorts of patient coronavirus COVID-19 COVID-19 vaccine Day event Factor first dose Haemodialysis humoral Humoral response Isolation Kidney disease kidney transplant measure Most patient mRNA vaccines Odds ratio participant Patient patients Peritoneal dialysis Potential difference recipients reported Safety SARS-CoV-2 second dose severe coronavirus disease Spanish vaccination Vaccine vaccine dose were measured were recorded [DOI] 10.1093/ndt/gfab313 PMC 바로가기